Gemcitabine HCl 122111-03-9

.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}


Molecular Weight:

299.66 Gemcitabine HCl is a DNA Synthesis Inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.






Biological Activity


Gemcitabine induced NF-κB activity in BxPC-3, PANC-1, and MIA PaCa-2
cells and decreased the level of the NF-κB inhibitor IκBα in BxPC-3 and
PANC-1 cells. Treatment of BxPC-3 cells with low dose Gemcitabine for 48
hours results in a dose-dependent increase in NF-κB binding. In
contrast, NF-κB DNA binding is decreased in BxPC-3 cells treated with
the higher Gemcitabine doses for 48 h; however, 24-h treatment with
these higher doses increases NF-κB binding in BxPC-3 cells


Intratumoral NF-κB activity is significantly elevated (1.3- to 1.8-fold)
in the Gemcitabine-treated mice compared to the PBS-treated mice,
suggesting that Gemcitabine also induces NF-κB activation.






Method


BxPC-3, MIA PaCa-2, and PANC-1 cells are seeded in a 96-well plate.
After 24 hours, cells are treated with vehicle, DMAPT and/or Gemcitabine
for an additional 24 hours or 48 hours. Apoptosis is quantified using
the Cell Death Detection ELISA to detect the amount of cytoplasmic
histone-associated DNA fragments and expressed relative to
vehicle-treated cells.

Contact us if you need more details on 122111-03-9. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Gemcitabine HCl 122111-03-9、122111-03-9 Gemcitabine HCl. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : DNA Damage > DNA/RNA Synthesis Inhibitor